Bureaucrats, editor, reviewer, Administrators
2,392
edits
ALLHAT: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 26: | Line 26: | ||
==Major points== | ==Major points== | ||
According to ALLHAT, chlorthalidone was superior in preventing cardiovascular | According to ALLHAT, chlorthalidone was superior to a calcium channel blocker and an ACE inhibitor in preventing some cardiovascular outcomes, and it is preferred as the first-line agent in essential hypertension. Despite the better protection found with chlorthalidone, hydrochlorothiazide has been the most commonly used diuretic therapy in the United Stages. However, there is little, if any, evidence that hydrochlorothiazide alone reduces cardiovascular events. | ||
==Design== | ==Design== | ||
| Line 63: | Line 63: | ||
==Measured outcomes and results== | ==Measured outcomes and results== | ||
=== | ===Baseline Characteristics=== | ||
* Mean age: 67 years | * Mean age: 67 years | ||
* Male: 53% | * Male: 53% | ||
* BMI: 30 | |||
* Black: 35%; Hispanic: 19% | * Black: 35%; Hispanic: 19% | ||
* | * Eligibility risk factors: | ||
** Smoker: 22% | |||
** Atherosclerotic | |||
** T2DM: 36% | |||
* History of CHD at baseline: 25% | |||
===Primary outcomes=== | ===Primary outcomes=== | ||
* Combined fatal coronary heart disease (CHD) or non-fatal MI: NS between all three groups | |||
* Combined fatal coronary heart disease (CHD) or non-fatal MI | |||
===Secondary outcomes=== | ===Secondary outcomes=== | ||
* All-cause mortality | * All-cause mortality: NS between all three groups | ||
* Fatal and nonfatal stroke | * Fatal and nonfatal stroke | ||
** Lisinopril group had 15% higher risk for stroke (p=0.02) | ** Lisinopril group had 15% higher risk for stroke (p=0.02) | ||